Upcoming Event

Third Annual London Macro Conference

11/12/2019 To 11/13/2019 London, UK

Since our founding, our Macro Research team has built its research product on four basic principles:
Utility. Humility. Simplicity. Quality. Coupling rigorous analytical process with intellectual flexibility, Strategas seeks to provide clear and concise research that yields timely and actionable investment conclusions.

The Strategas Capital Markets team leverages decades of experience and the full breadth of our macro research capabilities to provide corporate executives, and their boards, with actionable analytics, good counsel, innovative strategies and superior execution in an increasingly competitive and dynamic marketplace.

The best research is worthless unless it leads to an actionable conclusion. Strategas' “first principles” approach to research and idea generation has generated significant client demand such that the Firm formed Strategas Asset Management,
a registered investment advisor, to offer a range of managed account strategies to leverage the thematic investment conclusions and actionable ideas of the Firm’s macro research teams.

Turning Insight into Action
Our Firm

Our Firm

Strategas is an institutional brokerage and advisory firm serving clients in more than twenty countries around the world. Founded in 2006 by Jason DeSena Trennert, Nicholas Bohnsack, and Don Rissmiller, the Firm provides Macro Research and Capital Markets & Corporate Advisory services to institutional managers and corporate executives and through Strategas Asset Management manages a suite of macro thematic investment strategies by institutional mandate and for ultra and high-net-worth investors.
img

Strategy

10/15/2019 Bohnsack

October Asset Allocation Update

We remain somewhat skeptical of the prospects for even a “skinny” phase 1 deal between China and the U.S. to be stamped complete in a month’s time without a repeat of headline mudslinging that has negatively dominated the process throughout.  
Today’s Research

Policy Research

10/15/2019 Clifton

Whispers of New Presidential Candidates Growing

We look at the options for new candidates to enter the presidential race, Biden's polling is off his lows, news about Ukraine is deteriorating for Trump, a majority of voters now support impeachment, and Pelosi’s drug pricing legislation could cost pharma and biotech companies $500bn to $1tn of revenue over 10 years.
Today’s Research

Economics

10/15/2019 Rissmiller

Tariffs Continue To Look Deflationary

There was a boost in U.S. core CPI inflation in 3Q, but not enough to stay above the recent sideways channel ... 
Today’s Research

Technical Research

10/15/2019 Verrone

Bond/Gold Flows Aggressive, Shipping Bottoming, Banks Better 

While the day’s high/low S&P range was just 33 basis points, what wasn’t so benign was the spike in the put/call ratio (again in the 95th percentile).  
Today’s Research

Strategy

10/14/2019 Research Team

Weekly Market Catechism

In an effort to aggregate, in one place, answers to the questions we have been most frequently asked during our travels and in conversations with clients, we publish the Strategas Weekly Market Catechism at the beginning of each week.